The relation between the use of different hormonal contraceptives and antidepressant therapy was investigated.
INTRODUCTION
Mental disorders are among the most burdensome of diseases due to their high prevalence and they are positively related to socioeconomic measures of disadvantage. 1 Depression and anxiety are common in adolescence, the stage at which most mental disorders begin [1] [2] [3] , although they are often first detected later in life. 2 Epidemiological research from different parts of the world has revealed that the lifetime prevalence of depression in women is roughly twice that in men. 4 Likewise, self-reported studies on behavioural and emotional problems report differences between genders in adolescents. [5] [6] [7] [8] However, major depression is a multifactor disorder including predisposing genetic influences 9 and no fully satisfactory explanation for the gender difference has been proposed. 4, 10 Many different combined hormonal contraceptives (CHCs) and progestin-only hormonal contraceptives are available worldwide. They are effective means of preventing pregnancy 11 and of achieving a proper cycle control 12 . Although ideas about their association with mental disorders vary, it is commonly believed that hormonal contraceptives have no impact on depressive symptoms and only minimal, if any, impact on mood. [13] [14] [15] On the other hand, emotional side effects are suggested as reasons for discontinuing/switching treatment. 16 Furthermore, different side effects of hormonal contraceptive use on mood have been described; these appear to depend on the relation between oestrogen and progestin, and on the type of progestin. 17 Mental disorders such as depression and anxiety are more common in women who have reported adverse mood effects from either current or past treatment with combined oral contraceptives (COCs) than in those without such side effects during COC treatment. 18 This finding may support the theory that it is not the hormonal contraceptives as such that induce the mood swings but instead a vulnerability to mood deterioration in certain individuals. In order to further investigate the occurrence of mood disorders in users of different hormonal contraceptives we assessed the simultaneous use of antidepressants among the entire population of young women in Sweden. Hence, the aim of this study was to explore the relation between use of different hormonal contraceptives and antidepressant therapy. This register study comprised all 917 993 female residents in Sweden aged 16 to 31 on 1 November 2008 . Sweden has a total population of about 9.3 million. The study employed a cross-sectional design and the study population was separated into hormonal contraceptive users and non-users as well as into antidepressant users and non-users. have ATC-codes G03AA or G03AB whereas progestin-only contraceptives have the ATCcode G03AC. Thus, the contraceptive data included oral contraceptives as well as other contraceptive formulations. In addition to the ATC-code, the year of birth was extracted for each individual. All data were anonymous. Although the correct designation for data from the Swedish Prescribed Drug Register is, strictly speaking, "prescribed and dispensed drugs", the term used in this article is "drug users". To be considered as a contraceptive or antidepressant user the woman had to have the actual drug dispensed at least once during the three-year period. All of the drugs referred to in this article are generic drugs.
METHODS

Design and study population
Data collection
The total number of women in each specific group in the nation was identified from the Total Population Register, which is available on Statistics Sweden's website. 20 The difference between the total number of individuals and the number obtained from the Swedish Prescribed Drug Register represented data on non-users of both contraceptives and antidepressants. Each non-user was given a unique code which was inserted into the data set. Thus, a data set was obtained consisting of all Swedish women aged 16 to 31.
Statistical analyses
Numbers and percentages of users are given for the whole group of women aged 16-31, as well as for the age subgroups 16-19, 20-23, 24-27 , and 28-31 years. By logistic regression, with antidepressant user as a dependent variable, age-adjusted odds ratios (ORs) with 95%
confidence intervals (CIs) were calculated for those using solely a CHC and those using solely a progestin-only contraceptive versus non-hormonal contraceptive users. Similar analyses were carried out on subjects using both of these generic drugs, i.e. those who switched from using a CHC to using a progestin-only compound -or vice versa -during the three-year period. Analogous ORs were determined for each age group separately. The magnitude of the difference between ORs for CHC and progestin-only use in relation to antidepressant use was calculated as a ratio between these ORs.
Ethical approval
This study was approved by the Local Ethics Committee at Linköping University; Dnr M125-08.
RESULTS
Drug use
In the female Swedish population aged 16-31 on 1 November 2008, 540 249 (58.9%) subjects were hormonal contraceptive users and 78 436 (8.5%) antidepressant users, i.e. they had received a prescription and had it filled at least once during the three-year period. Among the hormonal contraceptive users, 402 931 (74.6 %) had used a CHC at least once, 220 233 (40.8%) had used a progestin-only contraceptive at least once (Table 1) In proportion to all antidepressant users, the selective serotonin reuptake inhibitor (SSRI) users constituted 86.5% of the studied population (data not shown). A negligible number (n=208) of hormonal emergency contraception users were included in the progestin-only group (data not shown).
The frequency of dispensing contraceptive drugs during the three-year period ranged from 1 to 84 times (median = 3), and 10% of the individuals collected a prescription between 9-84 times. For antidepressant drugs the frequency of dispensing ranged from 1 to 304 times (median = 5), and 10% of the individuals took out the prescribed drug between 16 and 304 times.
Relation between the use of antidepressants and hormonal contraceptives
In the age interval studied, the OR for antidepressants was 1.31 (95% CI: 1.29 -1.34) in progestin-only users and 1.02 (1.00 -1.04) in CHC users ( Figure 1 ).
Antidepressant ORs (hormonal contraceptives versus no hormonal contraceptives) are higher among progestin-only users in every age group than among CHC users in the corresponding age groups but the magnitude of the difference decreases with age: it amounts to 67% (95% CI: 57-78%) among women 16-19 years old and to only 10% (95% CI: 6-14%) among those in the age group 28-31.
DISCUSSION
In this nationwide population-based study we explored the relation between the use of different hormonal contraceptives and antidepressants among young women of different ages. Our main finding is that antidepressant therapy is more common among progestin-only users in every age group than among users of combined contraceptives. The largest difference was observed in the youngest age group with 67% higher antidepressant use among progestin-only users than among CHC users.
Hormonal contraceptives are easy to use, are highly effective and provide women means of controlling their reproductive and sexual health. Still, questions remain about their potential for causing symptoms of depression. Duke et al. 13 studied oral contraceptive use in young Australian women and found no independent effect on symptoms of depression. To be able to compare their study to ours, we carried out a non-stratified analysis (i.e. progestin-only and CHC users were combined) of data on women grouped according to age in the same way as the Australian authors had done, and reached a similar result: we found a non-significant OR amounting to 0.97 whereas the OR they calculated, which was also non-significant, was 1.05.
In contrast to the study by Duke et al. 13 , Kulkarni et al. found that COCs can cause mood disorders as an unwanted side-effect. 17 This finding corresponds with our results for the CHC users in the youngest age groups but not for the total population of CHC users. Interestingly, for those aged 20 to 27, our findings suggest that CHC users employ antidepressants less often than do non-contraceptive users. However, it is important to be aware of differences in data constitution between the different studies when comparing results. For example, we included data on all hormonal contraceptives; in addition to contraceptive pills, hormonal contraceptive formulations such as subcutaneous implants, injections, vaginal rings and transdermal patches were taken into consideration as well. Implants and injections are progestinonly contraceptives whereas the vaginal ring and the transdermal patch are CHCs. Since the relation between the use of hormonal contraceptives and antidepressant therapy, at least in our study, seems to depend strongly on age, the discrepancies between results from different studies may to some extent be an effect of the different ages of the study populations. In addition, factors such as a history of mental disorder, personality, troublesome relationships, socioeconomic problems, etc., may intervene in different combinations. They thus may influence and thereby confound the relation between use of hormonal contraceptives and the state of mood if no adjustment is made for these factors. However, the difference in antidepressant use between CHC and progestin-only users observed in our study might be a real unfavourable effect of progestin-only use on mood which is compensated for by ethinylestradiol in the CHC group. Another possible explanatory factor might be that the effects of progestins are more pronounced in teenagers than in older women.
Kendler et al. proposed a comprehensive model for depression suggesting that a combination of genetic, developmental, pharmacological and interpersonal factors may predict the development of depression and thereby explain the aetiology of this disorder. 9, 21 Apart from the daily burden that depression places on individuals, in young people depression also increases the risk of suicide. Since adolescence is already a period of greater risk of suicide any additional factor is of great importance. 22 Women are twice as likely as men to experience depression and are particularly vulnerable to mood disorders during their reproductive years. 4, 5 This might support Kendler's theory of a biological basis and a relation between mood disorders and changes in sex steroid levels as these hormones exert pronounced effects on brain areas that are involved in mood and cognition. 6, [23] [24] [25] [26] In a review article by Kuehner 23 , presenting gender differences in unipolar depression, it has also been postulated that the explanation lies in differences in gender roles.
Our analyses lack adjustments for possible confounding factors such as stressful life events, which are strong risk factors for depression in women, 9 and also for any history of mental disorder, personality problems, troublesome relationships, socioeconomic problems and the crises that are regarded as an ordinary part of growing up. These factors would only have an effect on the differences in antidepressant ORs (contraception / no contraception) between users of generic drugs if they were associated solely with users of CHCs or solely with users of progestins. This might arise, for example, if caregivers would believe that prescribing progestin-only treatment is preferable to prescribing CHC for women with former mood problems. It is important to bear in mind that this definitely is a possible confounder. In general, when using register data in research, major advantages are large populations and information free from recall bias. However, the possible misclassification of data must be taken into consideration. This concerns, for instance, the completeness of registration of individuals and the accuracy and degree of completeness of the registered data and the registration period. 31 The Swedish Prescribed Drug Register covers all drugs dispensed from all Swedish pharmacies and thus, since data are transferred directly from the cashier's computer to the register, the completeness of the register is reasonably high. Therefore, misclassification problems are probably a minor issue and the registered frequency of dispensed drugs is almost certainly correct. Only a small percentage of women can be identified as having purchased large numbers of prescription drugs; quite a few of them probably had switched from one type of hormonal contraceptive to another and/or from one antidepressant to another.
A registration period of three years was the period for which data were available when this study was planned and a longer time-frame would probably not change or strengthen the results. A weakness in this study is possibly the cross-sectional approach over the three-year period. We do not know the sequence of drug use for an individual i.e. whether a person was an antidepressant user before starting to use a contraceptive or the other way around. Therefore it is possible that the results are to some extent an effect of the preferential prescription of progestin-only contraceptives for women already identified as having a tendency to have mood problems. Future, prospectively designed studies registering data for a longer period will allow the sequence of drug use to be evaluated.
CONCLUSION
To our knowledge, this is the first study comparing the relation between age-specific drug use of different types of hormonal contraceptives and antidepressant therapy, using a national register of prescribed and dispensed drugs. Stratification of age and generic drugs showed variations between age groups and type of hormonal contraceptives and demonstrates therefore the importance of analysing subgroups. We conclude that progestin-only users are more liable to use antidepressants than are users of CHCs; this is particularly evident among teenagers. As progestin-only contraceptives seem to be a precipitating and/or perpetuating factor in mood disorders in vulnerable women, counsellors and prescribers of hormonal contraception should pay careful attention to women with a history of mood disorders and to those who have experienced lowered mood when taking a hormonal contraceptive. Likewise, mental healthcare givers should take contraceptive histories from their female patients.
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